Volume 14, Number 1—January 2008
Streptococcus suis in Humans, Thailand
To the Editor: Streptococcus suis is an important zoonotic pathogen for swine and humans. Among 33 serotypes, serotype 2 is more frequently isolated from diseased pigs than other serotypes (1). However, not all serotype 2 strains are virulent, and degree of virulence varies among strains (2). Previous studies have reported several S. suis putative virulence factors, including the polysaccharide capsule, the muramidase-released protein, the extracellular factor, and suilysin (3–5). Some of these factors have been used as virulence-associated markers, and the association of the factors of S. suis isolates with virulence or clinical background has been suggested in Europe (2,5). However, because many virulent isolates lacking these factors have also been isolated from clinical cases in Canada (6), they cannot be used as virulence markers in North America.
Recent analysis of S. suis isolates by multilocus sequence typing (MLST) suggested the association of some clonal groups with particular clinical manifestations. That is, most invasive isolates belonged to the sequence type (ST) 1 complex, while the ST27 and ST87 complexes were found to include a higher proportion of lung isolates (7). Although S. suis has been prevalent worldwide, the geographic location of the isolates used so far was mainly Europe, North America, and East Asia (7–9). Moreover, the clonal association with virulence of S. suis has been discussed mainly on the basis of clinical and experimental data in swine (7). In this report, to broaden understanding of the population structure of S. suis as a zoonotic agent, we characterize 20 S. suis isolates (Table) recovered from humans in Thailand in 1998–2002.
Serotyping by coagglutination tests showed that 19 of the 20 isolates belonged to serotype 2, while the remaining 1 (MNCM07) was serotype 14. MLST analysis resolved the 20 isolates into 8 STs (Table). By using eBURST (http://eburst.mlst.net), we assigned 4 isolates (MNCM01, MNCM06, MNCM07, and MNCM16) from 1 case of endocarditis and 3 cases of meningitis to the ST1 complex. The remaining isolates were assigned to the ST27 complex with a less-stringent group definition (Table), although ST101 (MNCM21) and ST104 (MNCM50) shared only 2 alleles with ST27 and were incorporated into this complex by a chaining effect. Regarding the clinical cases from which the ST27 complex isolates were recovered, the patients had meningitis, endocarditis, septicemia, septic shock, diarrhea, and respiratory involvement. The 2 ST complexes both contained isolates from deceased patients (Table).
All the isolates assigned to the ST1 complex were positive for the suilysin gene sly, the extracellular factor gene epf or its variant, and the muramidase-released protein gene mrp or its variant. With the exception of MNCM21 and MNCM50, which had only sly, all isolates classified into the ST27 complex were negative for sly and epf but positive for mrp or its variant. These results showed the congruence between STs and the virulence-associated gene profiles and further support the usefulness of MLST for epidemiologic studies of S. suis.
Of the 3 major clonal complexes identified so far in S. suis (ST1, ST27, and ST87), the ST1 complex particularly attracts considerable public attention as a clonal group that may have the potential for a higher degree of virulence than the others (7), and most (96%) of the human isolates investigated so far, including ST7 isolates, which caused the largest outbreak in China, belong to the ST1 complex (7–9). In this study, although no ST7 isolate was found, 4 isolates were assigned to the ST1 complex. This further confirmed the gravity of the ST1 complex not only for swine industries but also for public health.
In contrast to the ST1 complex, only 4 human clinical isolates have so far been reported to belong to the ST27 complex. Three of the 4 are isolates from Canada that belong to ST25 (7). The remaining 1 is from Japan and assigned to ST28 (8). Unlike in previous reports, 80% of the human clinical isolates (16 isolates) characterized in this study were assigned to the ST27 complex. Although previous studies suggested that members of the ST27 complex may have lower potential to cause invasive diseases in swine (7), all the isolates were isolated from blood or cerebrospinal fluid of the patients, suggesting a high degree of invasiveness (Table). Because it is unknown whether the ST27 complex is also dominant among isolates from diseased pigs in Thailand, future surveillance will be necessary to know the situation in pigs. However, our data indicate that the ST27 complex is another clonal group that should be assessed for its importance for human infection. Because mrp, epf, and sly are not appropriate as virulence markers for the ST27 complex members, development of novel virulence markers will be needed for efficient discrimination of S. suis strains virulent for humans.
This study made use of the Streptococcus suis Multilocus Sequence Typing website (http://ssuis.mlst.net); this site is hosted at Imperial College and development is funded by the Wellcome Trust. The study was supported by a grant-in-aid from the Zoonoses Control Project of the Ministry of Agriculture, Forestry and Fisheries of Japan and the Endowment Fund for Medical Research, Faculty of Medicine, Chiang Mai University.
- Staats JJ, Feder I, Okwumabua O, Chengappa MM. Streptococcus suis: past and present. Vet Res Commun. 1997;21:381–407.
- Vecht U, Wisselink HJ, van Dijk JE, Smith HE. Virulence of Streptococcus suis type 2 strains in newborn germfree pigs depends on phenotype. Infect Immun. 1992;60:550–6.
- Jacobs AAC, Loeffen PLW, van den Berg AJG, Storm PK. Identification, purification, and characterization of a thiol-activated hemolysin (suilysin) of Streptococcus suis. Infect Immun. 1994;62:1742–8.
- Smith HE, Damman M, van der Velde J, Wagenaar F, Wisselink HJ, Stockhofe-Zurwieden N, Identification and characterization of the cps locus of Streptococcus suis serotype 2: the capsule protects against phagocytosis and is an important virulence factor. Infect Immun. 1999;67:1750–6.
- Vecht U, Wisselink HJ, Jellema ML, Smith HE. Identification of two proteins associated with virulence of Streptococcus suis type 2. Infect Immun. 1991;59:3156–62.
- Gottschalk M, Lebrun A, Wisselink H, Dubreuil JD, Smith H, Vecht U. Production of virulence-related proteins by Canadian strains of Streptococcus suis capsular type 2. Can J Vet Res. 1998;62:75–9.
- King SJ, Leigh JA, Heath PJ, Luque I, Tarradas C, Dowson CG, Development of a multilocus sequence typing scheme for the pig pathogen Streptococcus suis: identification of virulent clones and potential capsular serotype exchange. J Clin Microbiol. 2002;40:3671–80.
- Chang B, Wada A, Ikebe T, Ohnishi M, Mita K, Endo M, Characteritics of Streptococcus suis isolated from patients in Japan. Jpn J Infect Dis. 2006;59:397–9.
- Ye C, Zhu X, Jing H, Du H, Segura M, Zheng H, Streptococcus suis sequence type 7 outbreak, Sichuan, China. Emerg Infect Dis. 2006;12:1203–8.
- Silva LMG, Baums CG, Rehm T, Wisselink HJ, Goethe R, Valentin-Weigand P. Virulence-associated gene profiling of Streptococcus suis isolates by PCR. Vet Microbiol. 2006;115:117–27.
Suggested citation for this article: Takamatsu D, Wongsawan K, Osaki M, Nishino H, Ishiji T, Tharavichitkul P, et al. Streptococcus suis in humans, Thailand [letter]. Emerg Infect Dis [serial on the Internet]. 2008 Jan [date cited]. Available from http://wwwnc.cdc.gov/eid/article/14/1/07-0568
Please use the form below to submit correspondence to the authors or contact them at the following address:
Tsutomu Sekizaki, National Institute of Animal Health, 3-1-5 Kannondai, Tsukuba, Ibaraki 305-0856, Japan;
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: July 08, 2010
- Page last updated: July 08, 2010
- Page last reviewed: July 08, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)